Event Online NowRegister Now
Welcome to Q1 2019 Emerging Medical Technologies Spotlight
AVVie (Angel Valve Vienna) GmbH
AVVie GmbH has created a unique technology for cardiac mitral valve prolapse repair; the Mitral Butterfly® implant. The implant offers minimally invasive reconstruction of the mitral valve for degenerative mitral regurgitation (DMR), or mitral valve prolapse (MVP), due to elongation or rupture of the chordal apparatus. The device consists of a nitinol stent and a PTFE (polymer) matrix, which represents artificial chordae. It can be delivered either surgically or via a transvascular approach onto the compromised segment of the valve in a minimally invasive procedure, with no need for open-heart surgery.
Consultant US Operations
We are seeking safe and efficient solutions that deliver minimally invasive treatment in the following fields:
-Flexible endoscopic procedures in the Gastrointestinal & Respiratory fields
-Laparoscopic surgery & Gynecological surgery in the General Surgery field
-Flexible or rigid endoscopic procedures in the Urology & Gynecology fields
-Flexible endoscopic procedures in the Ear, Nose and Throat field
Please contact us: medtech_innovation@Olympus.com
(Note) Any ideas, documents or information submitted in contacting us should be on a non-confidential basis. All ideas must have a patent filing.
Adan Medical Innovation
Our technology combines an app with a smartcase for autoinjectors to help patients manage their condition. Our first product, anAPPhylaxis, is for allergic individuals that have to carry at all times 2 epinephrine autoinjectors to prevent death in case of anaphylaxis, an extreme allergic reaction.
For more than 30 years Ximedica has provided a unique growth platform enabling organizations to successfully deploy medical technology products into the market. Ximedica was formed in 1985 by two Rhode Island School of Design (RISD) graduates, Aidan Petrie and Stephen Lane. From those earliest days to today, the application of "human-centered" design thinking to the innovation and product creation processes remains central to the company's success. In 2014 SV Life Sciences purchased a majority stake in the firm, recognizing that Ximedica is unique in providing a comprehensive service platform - a much needed option in the evolving ecosystem of outsourced medical device development. Throughout its history Ximedica has unearthed new opportunities for clients, solved difficult development challenges, delivered cutting edge innovative solutions and added considerably to patent counts. www.ximedica.com
Director of Innovation
CDx is a development stage diagnostics company with a proprietary technology and ready to market high-performance, low-cost blood-based tests for early detection and diagnosis of cancer, when it can be treated and cured.
President & CEO
Company is developing a device therapy for Gastroesophageal Reflux Disease (GERD). The device is injected in the lower esophagus in a one-time procedure during GI endoscopy with no overnight hospital stay.
President & CEO
Richard - Chip Corrigan
Use of low frequency ultrasound to deliver unformulated therapeutics such as mRNA, siRNA, macromolecules directly into tissue. Initial focus on gastrointestional system and skin diseases.
We are on a mission to close more wounds. Our technology allows surgeons to quickly yet gently stretch skin and close wounds that are not able to be closed with standard suture technique. This makes a whole category or wounds that usually require a skin graft or skin flap now closeable in a simple linear fashion. Our target market is skin cancer surgery.
The TwinFlo™ Catheter is designed to treat and protect the ischemic brain by providing rapid and selective cerebral hypothermia. It will offer a major advancement to the technology and treatment paradigms available to patients facing serious neurological damage and death. The unique design of TwinFlo™ results in more rapid and deeper localized cooling of the brain, while maintaining the remainder of the body at normal temperature (selective hypothermia). This differs from other hypothermia treatments that are unable to bring the brain to a sufficiently low temperature without significant total-body cooling and detrimental systemic effects. The design also permits selective drug and/or device delivery concurrent with the hypothermia treatment.